These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 16336462)

  • 1. Pegylated interferon-induced eyelid and eyebrow trichomegaly during chronic hepatitis C.
    Howaizi M
    J Gastroenterol Hepatol; 2005 Dec; 20(12):1945-6. PubMed ID: 16336462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Porphyria cutanea tarda as a complication of therapy for chronic hepatitis C.
    Azim J; McCurdy H; Moseley RH
    World J Gastroenterol; 2008 Oct; 14(38):5913-5. PubMed ID: 18855993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversible alopecia universalis secondary to PEG-interferon alpha-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus infection.
    Kartal ED; Alpat SN; Ozgunes I; Usluer G
    Eur J Gastroenterol Hepatol; 2007 Sep; 19(9):817-20. PubMed ID: 17700271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eyelash and eyebrow trichomegaly induced by interferon-alfa 2a.
    Goksugur N; Karabay O
    Clin Exp Dermatol; 2007 Sep; 32(5):583-4. PubMed ID: 17509059
    [No Abstract]   [Full Text] [Related]  

  • 5. [Side effect of pegylated-interferon treatment in chronic C hepatitis: agranulocytosis].
    Halász T; Farkas A; Tolvaj G; Horváth G
    Orv Hetil; 2006 Feb; 147(7):321-4. PubMed ID: 17489160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Occurrence of porphyria cutanea tarda during peginterferon/ribavirin therapy for chronic viral hepatitis C.
    Thevenot T; Bachmeyer C; Hammi R; Dumouchel P; Ducamp-Posak I; Cadranel JF
    J Hepatol; 2005 Apr; 42(4):607-8. PubMed ID: 15763350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cutaneous reactions induced by pegylated-interferon plus ribavirin combination therapy in a patient with chronic hepatitis C].
    Enjoji M; Dainichi T; Gondo H; Urabe K
    Fukuoka Igaku Zasshi; 2007 Sep; 98(9):353-6. PubMed ID: 17974079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alopecia universalis: a rare side effect seen on chronic hepatitis C treatment with peg-IFN and ribavirin.
    Demirturk N; Aykin N; Demirdal T; Cevik F
    Eur J Dermatol; 2006; 16(5):579-80. PubMed ID: 17101483
    [No Abstract]   [Full Text] [Related]  

  • 9. Interstitial pneumonitis after combination therapy with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C.
    Chen YC; Lu SN; Lin MC
    Chang Gung Med J; 2007; 30(1):92-7. PubMed ID: 17477035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutaneous sarcoidosis associated with pegylated interferon alfa and ribavirin therapy in a patient with chronic hepatitis C.
    Rogers CJ; Romagosa R; Vincek V
    J Am Acad Dermatol; 2004 Apr; 50(4):649-50. PubMed ID: 15034524
    [No Abstract]   [Full Text] [Related]  

  • 11. Adverse skin reactions due to pegylated interferon alpha 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus.
    Hashimoto Y; Kanto H; Itoh M
    J Dermatol; 2007 Aug; 34(8):577-82. PubMed ID: 17683392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Skin lesions in a patient on therapy for chronic hepatitis C.
    Hisamuddin K; Veluru C; Mullen KD
    Clin Gastroenterol Hepatol; 2009 Jun; 7(6):A24. PubMed ID: 19166978
    [No Abstract]   [Full Text] [Related]  

  • 13. Porphyria cutanea tarda during interferon/ribavirin therapy for chronic hepatitis C.
    Jessner W; Der-Petrossian M; Christiansen L; Maier H; Steindl-Munda P; Gangl A; Ferenci P
    Hepatology; 2002 Nov; 36(5):1301-2. PubMed ID: 12395349
    [No Abstract]   [Full Text] [Related]  

  • 14. Adverse response to pegylated interferon therapy in two patients with chronic hepatitis C.
    Thomas WL; Ramos F; Hospenthal DR
    Hawaii Med J; 2003 Aug; 62(8):163-4. PubMed ID: 14533347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cutaneous sarcoidosis during pegylated interferon alpha and ribavirin treatment of chronic hepatitis C--a case report].
    Honsová E; Sticová E; Sperl J
    Cesk Patol; 2007 Jan; 43(1):27-30. PubMed ID: 17370474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pulmonary toxicity by pegylated interferon alpha-2a in a patient with chronic hepatitis C].
    Son BK; Sohn JH; Kim TY; Park YK; Jeon YC; Han DS
    Korean J Hepatol; 2007 Mar; 13(1):103-7. PubMed ID: 17380081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive factors for adverse dermatological events during pegylated/interferon alpha and ribavirin treatment for hepatitis C.
    Li Z; Zhang Y; An J; Feng Y; Deng H; Xiao S; Ji F
    J Clin Virol; 2014 Jul; 60(3):190-5. PubMed ID: 24830933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diffuse hypertrichosis in the course of hepatitis C treatment by IFN-alpha and ribavirin.
    Misery L
    J Interferon Cytokine Res; 2002 Aug; 22(8):881-2. PubMed ID: 12396727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyoderma gangrenosum and exacerbation of psoriasis resulting from pegylated interferon alpha and ribavirin treatment of chronic hepatitis C.
    Yurci A; Guven K; Torun E; Gursoy S; Baskol M; Akgun H; Ozbakir O; Yucesoy M
    Eur J Gastroenterol Hepatol; 2007 Sep; 19(9):811-5. PubMed ID: 17700270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoimmune thrombocytopenia induced by PEG-IFN-alpha plus ribavirin in hepatitis C.
    Demirturk N; Cevik F; Demirdal T; Aykin N; Aslan V
    Platelets; 2006 Aug; 17(5):340-3. PubMed ID: 16928608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.